2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Profiling, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Hemoglobinopathies, Sickle Cell Disease, Immunology, Immunodeficiency, Neutropenia, White Blood Cell Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, AML, MDS, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Pediatric
PAPER

6042 Younger non-first-degree vs. older first-degree related donor haplo-HCT for acute leukemia and MDS, a randomized, open-label, non-inferiority phase 3 trial

Yishan Ye, MD, Xiaoyu Lai2, Ting Chen3, Ying Lu4, Jimin Shi5, Yanmin Zhao6, Lizhen Liu7, Jian Yu8, Jia Chen Sr, MD9, Jianping Lan10, Kourong Miao11, Guifang Ouyang12, Luxin Yang13, Huarui Fu14, Yibo Wu Sr, MD,15, Lin Li16, Junjie Cao17, Fenfang Tong18, Xiaolu Song19, Zhile Chen20, Zhen Cai, MD,PhD21, Mohamad Mohty, MD, PhD22, Yajing Xu23, Xi Zhang, MD24, He Huang, MD, PhD25, Yi Luo26
1 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
2 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
3 Xinqiao Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, China
4 The Affiliated People's Hospital of Ningbo University, Ningbo, China
5 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
6 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
7 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
8 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
9 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
10 Department of Hematology, Zhejiang Provincial People's Hospital, Hangzhou, China
11 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
12 Department of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China
13 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
14 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
15 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
16 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
17 The Affiliated People's Hospital of Ningbo University, Ningbo, China
18 Department of Hematology, Xiangya Hospital, Central South University, Changsha, China
19 Department of Hematology, Zhejiang Provincial People's Hospital, Hangzhou, China
20 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
21 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
22 Saint-Antoine Hospital Sorbonne University, Paris, France
23 Department of Hematology, Xiangya Hospital, Central South University, Changsha, China
24 Xinqiao Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, China
25 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
26 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China

Background

The safety and efficacy of non-first-degree related donor (NFD) haploidentical hematopoietic cell transplantation (HAPLO) remains unclear, and its comparison with first-degree related (FD) HAPLO remains controversial. This trial evaluated the safety and efficacy of NFD HAPLO and compared younger NFD with older FD donors.

Methods

NFD-001 was a multicenter, randomized, open-label, non-inferiority, phase 3 trial to compare younger NFD donors (NFD arm) (age ≤ 40) with older FD donors (FD arm) (age > 50) for HAPLO in patients with acute leukemia or myelodysplastic syndrome. Participants were randomly assigned to the treatment arms in a 1:1 ratio using a dynamic balancing algorithm. The centers were required to apply identical transplant protocol for the two arms. The trial was registered with ClinicalTrials.gov, NCT04547049, and has been completed.

Participants

Between Sep 14, 2020 and September 25, 2025, 234 eligible participants were randomized from 8 centers across China. One donor in the NFD arm withdrew consent immediately after randomization, and one patient in the FD arm refused treatment after entering the sterile chamber. Among the 232 patients eligible and analyzable, the median follow-up was 21.4 months (95% CI, 10.3-33.3) for the NFD and 23.5 months (95% CI, 9.5-44.1) for the FD arm, respectively. No significant difference was observed on the primary endpoint 2-year OS, which was 78.2% (95% CI, 70.4-86.8) for younger NFD and 75.3% (95% CI, 67.2-84.4) for older FD; HR=0.93 (95% CI, 0.54 to 1.63; P = .8), respectively. The 2-year estimate of progression-free survival, cumulative incidence of NRM and relapse, 180-day cumulative incidence of grade II-IV acute GVHD and the 2-year cumulative incidence of moderate-severe chronic GVHD were not significantly different between the two arms. Additionally, younger NFD were associated with higher yield of CD34+ cells.

Interpretation

Younger NFD HAPLO was non-inferior to older FD HAPLO for acute leukemia and MDS.

Yishan Ye, MD: No relevant conflicts of interest to declare.